Ensifentrine manufacturers
- Ensifentrine
-
- $2.20
-
2026-04-17
- CAS:1884461-72-6
- Min. Order: 1KG
- Purity: 99%
- Ensifentrine
-
- $5.00
-
2026-04-10
- CAS:1884461-72-6
- Min. Order: 1KG
- Purity: 99% hplc
- Supply Ability: 500TONS
|
| | Ensifentrine Basic information |
| Product Name: | Ensifentrine | | Synonyms: | Urea, N-[2-[(2E)-6,7-dihydro-9,10-dimethoxy-4-oxo-2-[(2,4,6-trimethylphenyl)imino]-2H-pyrimido[6,1-a]isoquinolin-3(4H)-yl]ethyl]-;Ensifentrine;EnsifentrineQ: What is
Ensifentrine Q: What is the CAS Number of
Ensifentrine;Ensifentrina;Ensifentrinum;RPL 554,RPL554,inhaled,Inhibitor,RPL-554,Ensifentrine,bronchoprotective,inhibit,COPD,PDE4,anti-inflammatory,PDE3,Phosphodiesterase (PDE);Ensifentrine, 10 mM in DMSO;(E)-RPL-554 | | CAS: | 1884461-72-6 | | MF: | C26H31N5O4 | | MW: | 477.56 | | EINECS: | | | Product Categories: | APIS | | Mol File: | 1884461-72-6.mol |  |
| | Ensifentrine Chemical Properties |
| density | 1.29±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 25 mg/mL (52.35 mM; Need ultrasonic) | | form | Solid | | pka | 13.73±0.46(Predicted) | | color | Light yellow to green yellow | | InChIKey | CSOBIBXVIYAXFM-BYNJWEBRSA-N | | SMILES | N(CCN1/C(=N/C2=C(C)C=C(C)C=C2C)/C=C2C3=C(C=C(OC)C(OC)=C3)CCN2C1=O)C(N)=O |
| | Ensifentrine Usage And Synthesis |
| Uses | RPL 554 is a known drug candidate for respiratory diseases, particularly in patients with asthma or chronic obstructive pulmonary diseases. | | in vivo | Ensifentrine (RPL-554; 10 mg/kg; Oral administration; once) significantly inhibits eosinophil recruitment following antigen challenge in ovalbumin-sensitized guinea pigs[1].
The inhalation of dry powder containing Ensifentrine by conscious guinea pigs (25% in micronized lactose) 1.5 h before antigen exposure significantly inhibits the recruitment of eosinophils to the airways[1].
Exposure of conscious guinea pigs to inhalation of dry powder containing Ensifentrine (2.5%) in micronized lactose significantly inhibits histamine-induced plasma protein extravasation in the trachea and histamine-induced bronchoconstriction over a 5.5-h period[1]. | Animal Model: | Male Dunkin Hartley guinea pigs (200-300 g) injected with ovalbumin[1]. | | Dosage: | 10 mg/kg
| | Administration: | Oral administration; once | | Result: | Significantly inhibits eosinophil recruitment following antigen challenge in ovalbumin-sensitized guinea pigs. |
| | IC 50 | PDE3: 0.4 nM (IC50); PDE4: 1479 nM (IC50) |
| | Ensifentrine Preparation Products And Raw materials |
|